Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

US proposes reimbursement rate for Medicare Advantage 2025 payments

Published 01/31/2024, 04:17 PM
Updated 01/31/2024, 04:25 PM
© Reuters.

(Reuters) - The U.S. government on Wednesday proposed a 2025 reimbursement rate for Medicare Advantage plans run by private insurers that reflects an effective growth rate of 2.44% and a total increase of 3.7%.

The closely watched proposal, known as the "advance notice", will be used by companies such as UnitedHealth Group (NYSE:UNH) and Humana (NYSE:HUM) to bid this year for contracts for Medicare Advantage plans they will sell in 2025.

The government payment rates affect how much insurers charge for monthly premiums, which plan benefits they offer and ultimately, how much they can profit.

About 65 million people are enrolled in the government's Medicare program for people aged 65 and older or who are disabled. About 34 million are in the orginal Medicare and the rest are in plans run by health insurers but paid for by the government.

The government has a three-year plan to decrease payments for Medicare Advantage as part of an effort it said will bring them more in line with the orginal Medicare coverage.

The proposed rates typically change after feedback from the insurers, other entities and the public. The final rate announcement will be published on or before April 1, 2024.

Elevance Health and CVS Health Corp (NYSE:CVS)'s Aetna also offer Medicare Advantage.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.